Kezdőlap・Részvénylista・Natera Inc

Natera Inc

Lezárt

SzektorEgészségügy

316.05 1.35

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

311.85

Maximum

320.62

Fő mutatók
By Trading Economics
Bevétel	18M -67M
Értékesítés	56M 753M
Egy részvényre jutó nyereség	-0.47
Profit margin	-8.897
Munkavállalók	6,135
EBITDA	-866K -66M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+6.42% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 5.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	7.2B 46B
Előző nyitás	314.7
Előző zárás	316.05

Hangulat hírek alapján

By Acuity

23%

77%

44 / 340 Rangsor szerint Healthcare

Natera Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 12. 20:06 UTC

News

Event

Natera Inc shares are rising after analyst upgrades and support for a Phase 1 trial in Germany using its Latitude assay to monitor tumor DNA.

2026. aug. 11. 20:02 UTC

News

Natera Inc reported strong Q2 revenue of $752.8 million but shares are lower amid concerns over significant insider selling.

2026. aug. 10. 20:02 UTC

News

Social Media

Natera Inc shares are lower amid negative sentiment from insider selling, despite recent analyst upgrades and price target increases from Morgan Stanley and Barclays.

2026. aug. 7. 20:03 UTC

Social Media

News

Natera Inc. shares rise sharply after analyst upgrades and strong earnings. RBC Capital raised its price target to $350, citing robust revenue growth.

2026. aug. 6. 23:02 UTC

Social Media

News

Natera Inc reported second-quarter revenue of $752.8 million, exceeding expectations. The stock is trading higher after the market closed, following strong earnings results.

2026. aug. 5. 23:01 UTC

Event

Natera Inc announced an application for the Signatera test in Japan. Shares are trading lower in after-market hours following the announcement.

2026. aug. 4. 19:04 UTC

Natera Inc shares are rising amid a broader market rally and high trading volume, despite challenges from declining U.S. factory orders and falling oil prices.

2026. aug. 3. 19:23 UTC

News

Natera Inc. shares are higher today, reflecting broader market gains amid strong manufacturing data and significant increases in major technology stocks.

2026. júl. 31. 19:46 UTC

Social Media

Natera Inc shares are lower today, reflecting broader declines in the genomic sector despite earlier gains and a rebound through key moving averages.

2026. júl. 30. 17:51 UTC

News

Citi initiated coverage of Natera Inc with a Buy rating and a $300 price target, contributing to the stock's upward movement today.

2026. júl. 29. 22:02 UTC

Natera Inc. shares declined in after-market trading, reversing an initial uptick. The stock is below its 20-day moving average amid cautious market sentiment.

2026. júl. 28. 23:46 UTC

Natera Inc shares are higher in after-market hours, showing positive momentum despite remaining below their 20-day moving average after recent declines.

2026. júl. 27. 19:46 UTC

News

Natera Inc's shares are lower today, reflecting broader market trends amid a significant drop in crude oil prices affecting sentiment across sectors.

2026. júl. 24. 18:46 UTC

News

Natera Inc's shares are lower, retracing from earlier highs amid broader market dynamics and a drop in oil prices affecting various sectors.

2026. júl. 22. 18:36 UTC

News

Natera Inc shares are lower following a JAMA study showing its Signatera test's effectiveness for Merkel cell carcinoma, despite favorable sensitivity results.

2026. júl. 21. 18:36 UTC

Natera Inc shares are higher, reflecting positive sentiment in U.S. markets amid strong earnings from companies like General Motors and Novartis.

2026. júl. 20. 18:16 UTC

News

Natera Inc. shares are lower today, despite positive developments expanding access to its Prospera transplant test and increased revenue from higher testing volumes.

Társak összehasonlítása

Árváltozás

Natera Inc Előrejelzés

Célár

By TipRanks

6.42% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 332.81 USD 6.42%

Magas 375 USD

Alacsony 260 USD

20 Wall Street elemző 12 hónapos célárain alapulva a(z)Natera Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

20 ratings

Vétel

Tartás

Eladás

20 Wall Street elemző célárain alapulva a(z)Natera Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

44 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.